Key result
Dual antiplatelet therapy after acute coronary syndrome reduces ischemic events at the expense of a small increase in bleeding risk, requiring careful patient selection to balance these outcomes.
Population
Patients after Acute Coronary Syndrome (ACS)
Design
Review
Authors
Loading...
Emphasizes tailored DAPT selection post-ACS to balance risks; leaves open optimal duration and agents in high-risk subgroups.
Physicians must carefully balance the significant reduction in ischemic events against the small increase in bleeding risk when prescribing dual antiplatelet therapy post-ACS.
Islam et al. (2010) conducted a review in Acute coronary syndrome (ACS). Dual antiplatelet therapy (aspirin + clopidogrel) was evaluated. Dual antiplatelet therapy after acute coronary syndrome reduces ischemic events at the expense of a small increase in bleeding risk, requiring careful patient selection to balance these outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: